$KERX: I spoke w/ bull & bearabout Zerenex NCE "controversy" -- both thought issue was overblown, not likely to be a problem.— Adam Feuerstein (@adamfeuerstein) February 1, 2013-- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein
Shares of late-stage biopharma Cytokinetics increased following positive comments from an Needham analyst.
Shares of Omeros fell almost 10% after analysts' downgraded the biotech.
Trade-Ideas LLC identified Keryx Biopharmaceuticals (KERX) as a "perilous reversal" (up big yesterday but down big today) candidate